Quick Answer
Cytek Biosciences, Inc. reported Operating Income Loss of -$40.38 million for the year ending 2025.
- Cytek Biosciences, Inc. showed a decrease of -96.8% in Operating Income Loss from 2024 to 2025.
- This data is from Cytek Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$218.0 thousand | Q3 2020: $6.71 million | Q1 2021: $1.13 million | Q2 2021: $3.81 million | Q3 2021: $2.90 million | Q1 2022: -$2.36 million | Q2 2022: -$891.0 thousand | Q3 2022: $1.36 million | Q1 2023: -$12.16 million | Q2 2023: -$9.13 million | Q3 2023: -$6.42 million | Q1 2024: -$10.73 million | Q2 2024: -$8.53 million | Q3 2024: -$4.25 million | Q1 2025: -$14.98 million | Q2 2025: -$10.62 million | Q3 2025: -$9.19 million.
- Over the full 6 years of available data (2020 to 2025), Cytek Biosciences, Inc.'s Operating Income Loss has declined by 395.7%.
- Historical annual values: Fiscal year 2025: -$40.38 million | Fiscal year 2024: -$20.52 million | Fiscal year 2023: -$27.85 million | Fiscal year 2022: -$1.80 million | Fiscal year 2021: $9.16 million | Fiscal year 2020: $13.66 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: